Hologic (NASDAQ:HOLX) Updates Q2 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its second quarter 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.000-1.030 for the period, compared to the consensus estimate of 1.040. The company issued revenue guidance of $995.0 million-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Stock Up 1.7 %

HOLX stock traded up $1.22 during mid-day trading on Wednesday, hitting $72.80. The stock had a trading volume of 2,779,067 shares, compared to its average volume of 2,293,025. The stock has a market capitalization of $16.43 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 2.35 and a beta of 0.98. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic has a 1-year low of $68.61 and a 1-year high of $84.67. The company has a fifty day moving average of $72.91 and a 200 day moving average of $77.95.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. On average, equities analysts expect that Hologic will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the topic of several analyst reports. Raymond James increased their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Royal Bank of Canada increased their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research note on Monday. Morgan Stanley dropped their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.